ATE296112T1 - Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12 - Google Patents

Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12

Info

Publication number
ATE296112T1
ATE296112T1 AT96910650T AT96910650T ATE296112T1 AT E296112 T1 ATE296112 T1 AT E296112T1 AT 96910650 T AT96910650 T AT 96910650T AT 96910650 T AT96910650 T AT 96910650T AT E296112 T1 ATE296112 T1 AT E296112T1
Authority
AT
Austria
Prior art keywords
colitis
substance
animal
antibodies
effectiveness
Prior art date
Application number
AT96910650T
Other languages
English (en)
Inventor
Warren Strober
Ivan Fuss
Markus Neurath
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE296112T1 publication Critical patent/ATE296112T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
AT96910650T 1995-10-25 1996-03-29 Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12 ATE296112T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/547,979 US5853697A (en) 1995-10-25 1995-10-25 Methods of treating established colitis using antibodies against IL-12
PCT/US1996/004337 WO1997015327A1 (en) 1995-10-25 1996-03-29 Methods of treating established colitis using antibodies against il-12

Publications (1)

Publication Number Publication Date
ATE296112T1 true ATE296112T1 (de) 2005-06-15

Family

ID=24186934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96910650T ATE296112T1 (de) 1995-10-25 1996-03-29 Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12

Country Status (10)

Country Link
US (1) US5853697A (de)
EP (1) EP0862461B1 (de)
JP (2) JP4148533B2 (de)
AT (1) ATE296112T1 (de)
AU (1) AU710282B2 (de)
CA (1) CA2235866C (de)
DE (1) DE69634782T2 (de)
ES (1) ES2239329T3 (de)
MX (1) MX9803253A (de)
WO (1) WO1997015327A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683046B1 (en) * 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
KR100764256B1 (ko) * 1998-01-23 2007-10-05 에프. 호프만-라 로슈 아게 인간 인터루킨-12에 대한 항체
US7026456B1 (en) * 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
EP1085906B1 (de) * 1998-06-10 2008-08-13 Ophidian Pharmaceuticals, Inc. Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen
IL145134A0 (en) 1999-03-25 2002-06-30 Knoll Gmbh Human antibodies that bind human il-12 and methods for producing
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US7186507B2 (en) * 1999-12-09 2007-03-06 Indiana University Research And Technology Corporation Fluorescent in situ RT-PCR
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
MXPA06003663A (es) * 2003-10-03 2006-06-05 Pharmacia Corp Composiciones de un inhibidor selectivo de la ciclooxigenasa - 2 administrado en condiciones hipotermicas para el tratamiento de trastornos o lesion del sistema nervioso central mediados por isquemicos.
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
NZ583153A (en) 2004-12-21 2011-06-30 Centocor Ortho Biotech Inc Anti-IL-12 antibodies, epitopes, compositions, methods and uses
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
CA2607949C (en) * 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
DK1880001T3 (da) * 2005-05-31 2011-09-12 Iams Company Feline probiotiske lactobacilli
WO2007041219A2 (en) * 2005-09-30 2007-04-12 Centocor, Inc. Compositions and methods for il13 biomarkers
US7776331B1 (en) * 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
AU2008211600B8 (en) 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
NZ580379A (en) 2007-03-29 2012-10-26 Abbott Lab Crystalline anti-human il-12 antibodies
RU2497545C2 (ru) 2008-03-18 2013-11-10 Эбботт Лэборетриз Способ лечения псориаза (варианты)
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
NZ590816A (en) 2008-08-14 2013-02-22 Cephalon Australia Pty Ltd Anti-il-12/il-23 antibodies
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
SG179135A1 (en) * 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
EP3436477A2 (de) 2016-03-29 2019-02-06 Janssen Biotech, Inc. Verfahren zur behandlung von psoriasis mit erhöhter intervalldosierung von anti-il12- und/oder -23-antikörper
WO2018112232A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3793521A4 (de) 2018-05-18 2022-02-23 Janssen Biotech, Inc. Sichere und wirksame methode zur behandlung von lupus mit anti-il12/il23-antikörper
KR20230148273A (ko) 2018-09-24 2023-10-24 얀센 바이오테크 인코포레이티드 항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE140483T1 (de) * 1988-11-10 1996-08-15 Genetics Inst Natürlicher killerzellen-stimulationsfaktor
EP0790309B1 (de) * 1989-12-22 2007-07-25 F. Hoffmann-La Roche Ag Zytotoxischer Lymphozyten-Reifefaktor 40kD Untereinheit und monoklonale Antikörper spezifisch dafür
CA2121096A1 (en) * 1993-04-22 1994-10-23 Weng Tao Monoclonal antibodies to bovine cytokines
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
JPH0769895A (ja) * 1993-08-27 1995-03-14 Tokyo Tanabe Co Ltd 炎症性腸疾患治療剤
WO1995023865A1 (en) * 1994-03-03 1995-09-08 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases

Also Published As

Publication number Publication date
JP2000502991A (ja) 2000-03-14
EP0862461B1 (de) 2005-05-25
MX9803253A (es) 1998-09-30
WO1997015327A1 (en) 1997-05-01
AU5378696A (en) 1997-05-15
DE69634782T2 (de) 2006-03-23
EP0862461A1 (de) 1998-09-09
AU710282B2 (en) 1999-09-16
DE69634782D1 (de) 2005-06-30
JP2008169199A (ja) 2008-07-24
US5853697A (en) 1998-12-29
CA2235866A1 (en) 1997-05-01
JP4148533B2 (ja) 2008-09-10
ES2239329T3 (es) 2005-09-16
CA2235866C (en) 2010-09-28

Similar Documents

Publication Publication Date Title
DE69634782D1 (de) Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12
Lawton et al. Some effects of high velocity electrons on wood
NO20062715L (no) Skriningsanalyser og fremgangsmater for tumorbehanding
MXPA05004033A (es) Hidroxilasas de asparaginil y moduladores de las mismas.
DE69026615T2 (de) Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest
DE69724451D1 (de) Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
ATE353657T1 (de) Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
Kime et al. Treatment with arginine vasotocin alters mating calls and decreases call attractiveness in male túngara frogs
Luster et al. Alterations of the antibody response following in utero exposure to diethylstilbestrol
Kidney et al. Diagnostic value of alkaline phosphatase isoenzyme separation by affinity electrophoresis in the dog.
Sismondo Physical characteristics of the drumming of Meconema thalassinum
Phipps An experimental study of the behavior of amphipods with respect to light intensity, direction of rays and metabolism
Stout et al. Regulation of the phonotactic threshold of the female cricket, Acheta domesticus: juvenile hormone III, allatectomy, L1 auditory neuron thresholds and environmental factors
DE60027273D1 (de) ASSAY ZUR IDENTIFIKATION VON IgE-ANTIKÖRPER-SUPPRESSOREN
Buzsáki What does the “LTP model of memory” model?
DK0824696T3 (da) Fremgangsmåde og kit til at forudsige den terapeutiske reaktion på et medikament mod en malign tumor
Powell Probability of reinforcement and fixed-ratio responding: A model
Ossenkopp et al. Some behavioral factors related to the effects of cold-restraint stress in rats: A factor analytic—multiple regression approach
RU95102036A (ru) Способ определения спонтанной двигательной активности крыс
Holley et al. Performance differences on three components of the family pictures subtest among right and left temporal lobectomy patients
DE2832853C3 (de) Mittel zur Beschleunigung der Präzipitation des Immunkomplexes bei einem Radioimmunoassy
Valdez et al. An in Vivo Model to Investigate Lymphocyte‐Mediated Immunity During Acute Hemoparasitic Infections: Use of a Monoclonal Antibody to Selectively Deplete CD4+ T Lymphocytes from Thymectomized Calves
JÍRA SOME ASPECTS OF DIAGNOSIS OF TOXOPLASMOSIS
SCHMITERLÖW Depressor and pressor activity of extracts from the aortic wall of cattle.
Bergner et al. An effect of pyridine-2-aldoxime methiodide (2-PAM) on cholinesterase at motor end-plates

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties